Literature DB >> 2137904

Selective uptake of hematoporphyrin derivative into human cerebral glioma.

J S Hill1, A H Kaye, W H Sawyer, G Morstyn, P D Megison, S S Stylli.   

Abstract

The uptake of hematoporphyrin derivative (HpD) into human cerebral glioma was measured using a porphyrin extraction technique. Patients with cerebral glioma were injected with HpD at a dose of 5 mg/kg body weight 24 hours before surgery and photoradiation therapy (PRT). Biopsies of tumor, and where possible, adjacent brain and normal brain were taken for analysis of HpD uptake. HpD was selectively localized into all grades of glioma, and there was a direct correlation between the grade of glioma and HpD level in the tumor. The levels were highest in glioblastoma multiforme (mean uptake of 5.9 micrograms of HpD/g of tumor wet weight) and lower in the intermediate-grade anaplastic astrocytoma (mean uptake of 2.4 micrograms/g of tumor) and the low-grade astrocytoma (1.6 micrograms/g of tumor). Uptake into normal brain tissue taken from HpD-sensitized patients was 0.2 microgram/g. HpD was also localized into the "brain adjacent to tumor" region. The selective uptake into the low-grade glioma suggests that PRT may be of use as an adjuvant therapy in these tumors and the detection of HpD in this region indicates that PRT may control the spread of tumor infiltrating into the adjacent normal brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137904     DOI: 10.1097/00006123-199002000-00011

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

1.  Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma.

Authors:  J S Hill; S B Kahl; A H Kaye; S S Stylli; M S Koo; M F Gonzales; N J Vardaxis; C I Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

2.  Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors.

Authors:  Meic H Schmidt; Glenn A Meyer; Kenneth W Reichert; Joseph Cheng; Hendrikus G Krouwer; Kutlan Ozker; Harry T Whelan
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

3.  ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.

Authors:  M Sam Eljamel; Carol Goodman; Harry Moseley
Journal:  Lasers Med Sci       Date:  2007-10-10       Impact factor: 3.161

4.  Uptake and retention of the photosensitizer mono-L-asparthyl chlorine e6 in experimental malignant glioma.

Authors:  Hiroyuki Matsumura; Jiro Akimoto; Jo Haraoka; Katsuo Aizawa
Journal:  Lasers Med Sci       Date:  2007-08-17       Impact factor: 3.161

5.  Identification of intracranial liqor metastases of experimental stereotactically implanted brain tumors by the tumor-selective MRI contrast agent MnTPPS.

Authors:  R I Ernestus; L J Wilmes; M Hoehn-Berlage
Journal:  Clin Exp Metastasis       Date:  1992-09       Impact factor: 5.150

6.  Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer.

Authors:  J S Hill; S B Kahl; S S Stylli; Y Nakamura; M S Koo; A H Kaye
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

7.  Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy.

Authors:  K W Woodburn; S Stylli; J S Hill; A H Kaye; J A Reiss; D R Phillips
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

8.  Evaluation of a morpholinothiolporphyrin for use in photodynamic therapy.

Authors:  K W Woodburn; J S Hill; S Stylli; A H Kaye; J A Reiss; D R Phillips
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

9.  Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma.

Authors:  G Karagianis; J S Hill; S S Stylli; A H Kaye; N J Varadaxis; J A Reiss; D R Phillips
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

10.  YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.

Authors:  Krishanthan Vigneswaran; Nathaniel H Boyd; Se-Yeong Oh; Shoeb Lallani; Andrew Boucher; Stewart G Neill; Jeffrey J Olson; Renee D Read
Journal:  Clin Cancer Res       Date:  2020-11-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.